SURUNKALI V GEPATIT BILAN OG‘RIGAN BEMORLARDA JIGAR FIBROZINING YASHIRIN KECHISHI: INVAZIV BO‘LMAGAN TASHXIS USULLARINI (APRI, FIB-4 VA FIBROSKAN) QIYOSIY BAHOLASH
##article.subject##:
Surunkali gepatit B, jigar fibrozi, APRI, FIB-4, FibroScan, noinvaziv baholash##article.abstract##
Surunkali gepatit B (CHB) jiddiy global salomatlik yuki bo‘lib qolmoqda, jigar fibrozining rivojlanishi bemorning natijalarini hal qiluvchi hal qiluvchi omil hisoblanadi. An’anaviy jigar biopsiyasi oltin standart hisoblansa-da, o‘ziga xos xavf va cheklovlarga ega. Ushbu tadqiqot CHB bemorlarida jigar fibrozining rivojlanishini baholashda uchta invaziv bo‘lmagan usullar - APRI (AST-to-trombotsitlar nisbati indeksi), FIB-4 (Fibroz-4 indeksi) va FibroScan (o‘tkinchi elastografiya) diagnostik aniqligi va klinik foydasini baholaydi. 324 CHB bemorlarining istiqbolli kohort tadqiqoti 24 oy davomida o‘tkazildi. Barcha bemorlar APRI, FIB-4 va FibroScan yordamida bir vaqtning o‘zida baholashdan o‘tkazildi, jigar biopsiyasi 156 bemorda standart standart sifatida xizmat qildi. Diagnostika samaradorligi ROC tahlili, sezgirlik, o‘ziga xoslik va bashoratli qiymatlar yordamida baholandi. FibroScan sezilarli fibroz (≥F2) uchun yuqori diagnostika aniqligini AUROC 0,89 (95% CI: 0,85-0,93), undan keyin FIB-4 (AUROC: 0,81, 95% CI: 0,76-0,806, va APRIOC: 0,86) ko‘rsatdi. CI: 0,70-0,82). FibroScanning biokimyoviy markerlar bilan kombinatsiyasi diagnostika aniqligini 0,92 ga oshirdi (95% CI: 0,89-0,95). FibroScan CHB bemorlarida jigar fibrozini aniqlashda yuqori samaradorlikni namoyish etadi, shu bilan birga bir nechta invaziv bo‘lmagan usullarni birlashtirish diagnostika aniqligini oshiradi va invaziv jigar biopsiyasiga bo‘lgan ehtiyojni kamaytirishi mumkin.
Библиографические ссылки
World Health Organization. Global hepatitis report 2024. Geneva: World Health Organization; 2024.
European Association for the Study of the Liver. EASL 2024 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2024;81(2):346-402.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-526.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317-1325.
Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008;48(5):835-847.
Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713.
Kim BK, Kim DY, Park JY, et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546-553.
Verveer C, Zondervan PE, ten Kate FJ, et al. Evaluation of transient elastography for fibrosis assessment compared with large biopsies in chronic hepatitis B and C. Liver Int. 2012;32(4):622-628.
Li Y, Huang YS, Wang ZZ, et al. Systematic review with meta-analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B. Aliment Pharmacol Ther. 2016;43(4):458-469.
Seto WK, Lee CF, Lai CL, et al. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6(8):e23077.
Xu X, Su Y, Song R, et al. Performance of common imaging techniques vs serum biomarkers in assessing fibrosis in patients with chronic hepatitis B: a systematic review and meta-analysis. World J Gastroenterol. 2019;25(31):4373-4388.
Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182-1191.
Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454-462.
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-475.
European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264.
Petta S, Maida M, Macaluso FS, et al. The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology. 2015;62(4):1101-1110.
Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008;47(2):380-384.
Millonig G, Reimann FM, Friedrich S, et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology. 2008;48(5):1718-1723.
Liu H, Fu J, Hong R, et al. Acoustic radiation force impulse elastography for the non-invasive evaluation of hepatic fibrosis in patients with chronic hepatitis B. Hepatol Res. 2012;42(8):782-789.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology. 2005;41(1):48-54.
